Illumina Rallies as Investors Revisit Strong Q2 Results and Higher 2026 Outlook

Illumina (ILMN) is up 7.5% today. Here is some analysis on what might have caused this price movement.

Analysis: No clear same-day catalyst was easy to identify, so the move appears most likely tied to continued follow-through from Illumina’s late-July quarterly report and the wave of estimate and price-target resets that followed. This could also reflect investors rewarding stronger clinical sequencing demand, sustained NovaSeq X momentum, and a higher full-year outlook.

Details:

In its July 30 quarterly release, the company posted second-quarter revenue of $1.159 billion, up from $1.059 billion a year earlier, showing improving top-line momentum.

The company raised full-year guidance, including non-GAAP diluted EPS to $5.30-$5.40 from $5.15-$5.30, which likely helped support a more bullish earnings narrative.

Management highlighted strong demand for NovaSeq X and expanding use in sequencing-intensive clinical applications, reinforcing the view that instrument and consumables demand is stabilizing.

Several firms lifted their price targets after the quarter, and an August 10 rating roundup still showed notable upside targets from bullish analysts, which may have kept buyers engaged even without fresh news today.

Sources:

Illumina, SEC, TipRanks

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ILMN Insider Trading Activity

$ILMN insiders have traded $ILMN stock on the open market 56 times in the past 6 months. Of those trades, 0 have been purchases and 56 have been sales.

Here’s a breakdown of recent trading of $ILMN stock by insiders over the last 6 months:

KEITH A. MEISTER has made 0 purchases and 40 sales selling 1,740,183 shares for an estimated $303,134,502.
PATRICIA LECKMAN (SVP, Chief People Officer) has made 0 purchases and 9 sales selling 3,937 shares for an estimated $529,719.
SCOTT M DAVIES (Chief Legal Officer) has made 0 purchases and 4 sales selling 3,181 shares for an estimated $487,316.
SCOTT D ERICKSEN (VP, Chief Accounting Officer) has made 0 purchases and 2 sales selling 2,000 shares for an estimated $305,150.
CHRISTENSEN JAKOB WEDEL (SVP, Strategy/Corp Development) sold 700 shares for an estimated $97,328

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive ILMN Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ILMN Hedge Fund Activity

We have seen 461 institutional investors add shares of $ILMN stock to their portfolio, and 457 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 2,976,556 shares (+192.4%) to their portfolio in Q2 2026, for an estimated $523,367,841
SESSA CAPITAL IM, L.P. removed 2,157,475 shares (-65.9%) from their portfolio in Q2 2026, for an estimated $379,348,829
SOUTHPOINT CAPITAL ADVISORS LP removed 1,700,000 shares (-81.0%) from their portfolio in Q2 2026, for an estimated $298,911,000
PRIMECAP MANAGEMENT CO/CA/ added 1,447,350 shares (+70.0%) to their portfolio in Q2 2026, for an estimated $254,487,550
AGF MANAGEMENT LTD added 1,364,815 shares (+inf%) to their portfolio in Q2 2026, for an estimated $239,975,421
WELLINGTON MANAGEMENT GROUP LLP added 1,188,004 shares (+190.1%) to their portfolio in Q2 2026, for an estimated $208,886,743
JPMORGAN CHASE & CO added 1,181,215 shares (+inf%) to their portfolio in Q2 2026, for an estimated $207,693,033

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ILMN Government Contracts

We have seen $31,221,887 of award payments to $ILMN over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

ILLUMINA DRAGEN GENOMIC ANALYSIS SYSTEM: $1,189,411
PURCHASE OF 7 MISEQ I100S TO PERFORM WHOLE GENOME SEQUENCING (WGS) ON ALL FOODBORNE PATHOGENS ISOLATED AND ...: $805,796
ILLUMINA REAGENTS AND CONSUMABLES, EO 14398: $650,392
EASTERN LAB, MIDWEST LAB, WESTERN LAB QUARTER FOUR FY25 TASK ORDER FOR WGS KITS UNDER CONTRACT 1232SA25D000...: $625,942
MAINTENANCE AND SERVICE CONTRACT FOR VARIOUS GOVERNMENT-OWNED ILLUMINA SEQUENCING PLATFORMS AND ANCILLARY E...: $544,728

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$ILMN Price Targets

Multiple analysts have issued price targets for $ILMN recently. We have seen 9 analysts offer price targets for $ILMN in the last 6 months, with a median target of $185.0.

Here are some recent targets:

Vijay Kumar from Evercore ISI Group set a target price of $200.0 on 07/06/2026
David Westenberg from Piper Sandler set a target price of $200.0 on 07/01/2026
Subbu Nambi from Guggenheim set a target price of $200.0 on 06/29/2026
Eve Burstein from Bernstein set a target price of $185.0 on 06/26/2026
Luke Sergott from Barclays set a target price of $145.0 on 06/24/2026
Casey Woodring from JP Morgan set a target price of $185.0 on 06/10/2026
Dan Leonard from RBC Capital set a target price of $170.0 on 05/15/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.